FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4289444107> ?p ?o ?g. }

• W4289444107 endingPage "84.e12" @default.
• W4289444107 startingPage "84.e1" @default.
• W4289444107 abstract "Fetal growth restriction is strongly associated with impaired placentation and abnormal uteroplacental blood flow. Nitric oxide donors such as pentaerythritol tetranitrate are strong vasodilators and protect the endothelium. Recently, we demonstrated in a randomized controlled pilot study a 38% relative risk reduction for the development of fetal growth restriction or perinatal death following administration of pentaerythritol tetranitrate to pregnant women at risk, identified by impaired uterine perfusion at midgestation. Results of this monocenter study prompted the hypothesis that pentaerythritol tetranitrate might have an effect in pregnancies with compromised placental function as a secondary prophylaxis.This study aimed to test the hypothesis that the nitric oxide donor pentaerythritol tetranitrate reduces fetal growth restriction and perinatal death in pregnant women with impaired placental perfusion at midgestation in a multicenter trial.In this multicenter, randomized, double-blind, placebo-controlled trial, 2 parallel groups of pregnant women presenting with a mean uterine artery pulsatility index >95th percentile at 19+0 to 22+6 weeks of gestation were randomized to 50-mg Pentalong or placebo twice daily. Participants were assigned to high- or low-risk groups according to their medical history before randomization was performed block-wise with a fixed block length stratified by center and risk group. The primary efficacy endpoint was the composite outcome of perinatal death or development of fetal growth restriction. Secondary endpoints were neonatal and maternal outcome parameters.Between August 2017 and March 2020, 317 participants were included in the study and 307 were analyzed. The cumulative incidence of the primary outcome was 41.1% in the pentaerythritol tetranitrate group and 45.5% in the placebo group (unadjusted relative risk, 0.90; 95% confidence interval, 0.69-1.17; adjusted relative risk, 0.90; 95% confidence interval, 0.69-1.17; P=.43). Secondary outcomes such as preterm birth (unadjusted relative risk, 0.73; 95% confidence interval, 0.56-0.94; adjusted relative risk, 0.73; 95% confidence interval, 0.56-0.94; P=.01) and pregnancy-induced hypertension (unadjusted relative risk, 0.65; 95% confidence interval, 0.46-0.93; adjusted relative risk, 0.65; 95% confidence interval, 0.46-0.92; P=0.01) were reduced.Our study failed to show an impact of pentaerythritol tetranitrate on the development of fetal growth restriction and perinatal death in pregnant women with impaired uterine perfusion at midgestation. Pentaerythritol tetranitrate significantly reduced secondary outcome parameters such as the incidence of preterm birth and pregnancy-induced hypertension in these pregnancies." @default.
• W4289444107 created "2022-08-02" @default.
• W4289444107 creator A5001681978 @default.
• W4289444107 creator A5004153656 @default.
• W4289444107 creator A5008571928 @default.
• W4289444107 creator A5016802215 @default.
• W4289444107 creator A5022810762 @default.
• W4289444107 creator A5023332352 @default.
• W4289444107 creator A5024407539 @default.
• W4289444107 creator A5025265707 @default.
• W4289444107 creator A5033329658 @default.
• W4289444107 creator A5034204040 @default.
• W4289444107 creator A5039597423 @default.
• W4289444107 creator A5043109492 @default.
• W4289444107 creator A5044640003 @default.
• W4289444107 creator A5048541901 @default.
• W4289444107 creator A5051045029 @default.
• W4289444107 creator A5052026745 @default.
• W4289444107 creator A5054104985 @default.
• W4289444107 creator A5055003038 @default.
• W4289444107 creator A5057392429 @default.
• W4289444107 creator A5058770601 @default.
• W4289444107 creator A5064496990 @default.
• W4289444107 creator A5071230710 @default.
• W4289444107 creator A5071955622 @default.
• W4289444107 creator A5076516610 @default.
• W4289444107 creator A5077491832 @default.
• W4289444107 creator A5084823222 @default.
• W4289444107 creator A5087675041 @default.
• W4289444107 creator A5088906991 @default.
• W4289444107 date "2023-01-01" @default.
• W4289444107 modified "2023-09-27" @default.
• W4289444107 title "Effect of pentaerythritol tetranitrate (PETN) on the development of fetal growth restriction in pregnancies with impaired uteroplacental perfusion at midgestation—a randomized trial" @default.
• W4289444107 cites W1761057373 @default.
• W4289444107 cites W1970388632 @default.
• W4289444107 cites W2019033274 @default.
• W4289444107 cites W2047808951 @default.
• W4289444107 cites W2049759667 @default.
• W4289444107 cites W2058987363 @default.
• W4289444107 cites W2114949397 @default.
• W4289444107 cites W2118232604 @default.
• W4289444107 cites W2129376438 @default.
• W4289444107 cites W2130105938 @default.
• W4289444107 cites W2468236598 @default.
• W4289444107 cites W2507799309 @default.
• W4289444107 cites W2519262228 @default.
• W4289444107 cites W2756444225 @default.
• W4289444107 cites W2772417060 @default.
• W4289444107 cites W2780475636 @default.
• W4289444107 cites W2916921366 @default.
• W4289444107 cites W2917958430 @default.
• W4289444107 cites W2970920598 @default.
• W4289444107 cites W3207420069 @default.
• W4289444107 cites W4249425993 @default.
• W4289444107 doi "https://doi.org/10.1016/j.ajog.2022.07.028" @default.
• W4289444107 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35931132" @default.
• W4289444107 hasPublicationYear "2023" @default.
• W4289444107 type Work @default.
• W4289444107 citedByCount "2" @default.
• W4289444107 countsByYear W42894441072023 @default.
• W4289444107 crossrefType "journal-article" @default.
• W4289444107 hasAuthorship W4289444107A5001681978 @default.
• W4289444107 hasAuthorship W4289444107A5004153656 @default.
• W4289444107 hasAuthorship W4289444107A5008571928 @default.
• W4289444107 hasAuthorship W4289444107A5016802215 @default.
• W4289444107 hasAuthorship W4289444107A5022810762 @default.
• W4289444107 hasAuthorship W4289444107A5023332352 @default.
• W4289444107 hasAuthorship W4289444107A5024407539 @default.
• W4289444107 hasAuthorship W4289444107A5025265707 @default.
• W4289444107 hasAuthorship W4289444107A5033329658 @default.
• W4289444107 hasAuthorship W4289444107A5034204040 @default.
• W4289444107 hasAuthorship W4289444107A5039597423 @default.
• W4289444107 hasAuthorship W4289444107A5043109492 @default.
• W4289444107 hasAuthorship W4289444107A5044640003 @default.
• W4289444107 hasAuthorship W4289444107A5048541901 @default.
• W4289444107 hasAuthorship W4289444107A5051045029 @default.
• W4289444107 hasAuthorship W4289444107A5052026745 @default.
• W4289444107 hasAuthorship W4289444107A5054104985 @default.
• W4289444107 hasAuthorship W4289444107A5055003038 @default.
• W4289444107 hasAuthorship W4289444107A5057392429 @default.
• W4289444107 hasAuthorship W4289444107A5058770601 @default.
• W4289444107 hasAuthorship W4289444107A5064496990 @default.
• W4289444107 hasAuthorship W4289444107A5071230710 @default.
• W4289444107 hasAuthorship W4289444107A5071955622 @default.
• W4289444107 hasAuthorship W4289444107A5076516610 @default.
• W4289444107 hasAuthorship W4289444107A5077491832 @default.
• W4289444107 hasAuthorship W4289444107A5084823222 @default.
• W4289444107 hasAuthorship W4289444107A5087675041 @default.
• W4289444107 hasAuthorship W4289444107A5088906991 @default.
• W4289444107 hasBestOaLocation W42894441071 @default.
• W4289444107 hasConcept C126322002 @default.
• W4289444107 hasConcept C131872663 @default.
• W4289444107 hasConcept C142724271 @default.
• W4289444107 hasConcept C168563851 @default.
• W4289444107 hasConcept C204787440 @default.
• W4289444107 hasConcept C27081682 @default.
• W4289444107 hasConcept C2775965419 @default.
• W4289444107 hasConcept C2778780700 @default.

• next